A new preclinical study in Nature reports a single-molecule therapy that combines GLP-1 and GIP receptor activation with triple PPAR agonism, delivering greater weight loss and metabolic benefits in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results